Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Richard White
Based on 9 articles published since 2010
(Why 9 articles?)

Between 2010 and 2020, Richard White wrote the following 9 articles about Melanoma.
+ Citations + Abstracts
1 Guideline The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. 2013

Kaufman, Howard L / Kirkwood, John M / Hodi, F Stephen / Agarwala, Sanjiv / Amatruda, Thomas / Bines, Steven D / Clark, Joseph I / Curti, Brendan / Ernstoff, Marc S / Gajewski, Thomas / Gonzalez, Rene / Hyde, Laura Jane / Lawson, David / Lotze, Michael / Lutzky, Jose / Margolin, Kim / McDermott, David F / Morton, Donald / Pavlick, Anna / Richards, Jon M / Sharfman, William / Sondak, Vernon K / Sosman, Jeffrey / Steel, Susan / Tarhini, Ahmad / Thompson, John A / Titze, Jill / Urba, Walter / White, Richard / Atkins, Michael B. ·Rush University Cancer Center, 1725 West Harrison Street, Chicago, IL 60612, USA. ·Nat Rev Clin Oncol · Pubmed #23982524.

ABSTRACT: Immunotherapy is associated with durable clinical benefit in patients with melanoma. The goal of this article is to provide evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with high-risk and advanced-stage melanoma in the USA. To achieve this goal, the Society for Immunotherapy of Cancer sponsored a panel of melanoma experts--including physicians, nurses, and patient advocates--to develop a consensus for the clinical application of tumour immunotherapy for patients with melanoma. The Institute of Medicine clinical practice guidelines were used as a basis for this consensus development. A systematic literature search was performed for high-impact studies in English between 1992 and 2012 and was supplemented as appropriate by the panel. This consensus report focuses on issues related to patient selection, toxicity management, clinical end points and sequencing or combination of therapy. The literature review and consensus panel voting and discussion were used to generate recommendations for the use of immunotherapy in patients with melanoma, and to assess and rate the strength of the supporting evidence. From the peer-reviewed literature the consensus panel identified a role for interferon-α2b, pegylated-interferon-α2b, interleukin-2 (IL-2) and ipilimumab in the clinical management of melanoma. Expert recommendations for how to incorporate these agents into the therapeutic approach to melanoma are provided in this consensus statement. Tumour immunotherapy is a useful therapeutic strategy in the management of patients with melanoma and evidence-based consensus recommendations for clinical integration are provided and will be updated as warranted.

2 Review Enhanced melanoma diagnosis with multispectral digital skin lesion analysis. 2018

Farberg, Aaron S / Glazer, Alex M / Winkelmann, Richard R / Tucker, Natalie / White, Richard / Rigel, Darrell S. ·Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. · Division of Dermatology, University of Arizona, Tucson, USA. · Department of Dermatology, OhioHealth, Athens, USA. · STRATA Skin Sciences, Horsham, Pennsylvania, USA. · IRIS Interactive Horizon Inc, Cody, Wyoming, USA. · Department of Dermatology, New York University School of Medicine, New York, USA. ·Cutis · Pubmed #29894523.

ABSTRACT: Multispectral digital skin lesion analysis (MSDSLA) is both sensitive and specific in the detection of malignant melanoma by dermatologists and nondermatologists, and data have shown that MSDSLA can be a valuable tool in the evaluation of pigmented skin lesions (PSLs). This study aimed to aggregate data from 7 prior studies to provide a comprehensive overview and evaluate the consistency of the effects of MSDSLA when used in conjunction with clinical examination and dermoscopy to evaluate PSLs.

3 Article Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. 2019

Klemen, Nicholas D / Han, Gang / Leong, Stanley P / Kashani-Sabet, Mohammed / Vetto, John / White, Richard / Schneebaum, Schlomo / Pockaj, Barbara / Mozzillo, Nicola / Charney, Kim / Hoekstra, Harald / Sondak, Vernon K / Messina, Jane L / Zager, Jonathan S / Han, Dale. ·Section of Surgical Oncology, Yale School of Medicine, New Haven, Connecticut. · Department of Epidemiology and Biostatistics, School of Public Health, Texas A&M University, College Station, Texas. · California Pacific Medical Center and Research Institute, San Francisco, California. · Division of Surgical Oncology, Oregon Health & Science University, Portland, Oregon. · Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina. · Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. · Mayo Clinic, Phoenix, Arizona. · Instituto Tumori Napoli Fondazione G. Pascale, Napoli, Italy. · St. Joseph Hospital of Orange, Orange, California. · University of Groningen, Groningen, Netherlands. · Moffitt Cancer Center, Tampa, Florida. ·J Surg Oncol · Pubmed #30883771.

ABSTRACT: BACKGROUND: Completion lymph node dissection (CLND) for sentinel lymph node (SLN) disease in melanoma patients is debated. We evaluated the impact of CLND on survival and assessed for predictors of nonsentinel node metastasis (positive CLND). METHODS: Positive SLN melanoma patients were retrospectively identified in the Sentinel Lymph Node Working Group database. Clinicopathological factors were correlated with CLND status, overall survival (OS), and melanoma-specific survival (MSS). RESULTS: There were 953 positive SLN patients of whom 831 (87%) had CLND. Positive CLND was seen in 141 (17%) cases and was associated with worse OS and MSS (both P < 0.001). CLND was not performed (No-CLND) in 122 of 953 positive SLN cases (13%), of whom 100 had follow-up and 18 (18%) developed a nodal recurrence (NR). No significant differences in OS and MSS were seen comparing CLND with No-CLND (P = 0.084, P = 0.161, respectively) and comparing positive CLND with No-CLND NR patients (P = 0.565, P = 0.998, respectively). Gender, primary site, ulceration, and number of positive SLNs were correlated with nonsentinel node metastasis. CONCLUSIONS: Performance of CLND provides prognostic information but is not associated with a survival benefit. Clinical variables can predict a positive CLND in patients who may be at high risk of recurrence.

4 Article The Impact of Quantitative Data Provided by a Multi-spectral Digital Skin Lesion Analysis Device on Dermatologists'Decisions to Biopsy Pigmented Lesions. 2017

Farberg, Aaron S / Winkelmann, Richard R / Tucker, Natalie / White, Richard / Rigel, Darrell S. ·Dr. Farberg is with the Icahn School of Medicine, Dermatology, at Mount Sinai in New York, New York. · Dr. Winkelmann is with Ohio Health, Dermatology, Columbus, Ohio. · Ms. Tucker is with STRATA Skin Sciences Inc. in Horsham, Pennsylvania. · Mr. White is with Iris Interactive System in Cody, Wyoming. · Dr. Rigel is with the New York University School of Medicine, Dermatology, in New York, New York. ·J Clin Aesthet Dermatol · Pubmed #29344323.


5 Article Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions. 2017

Farberg, Aaron S / Glazer, Alex M / White, Richard / Rigel, Darrell S. · ·J Drugs Dermatol · Pubmed #28628677.


Importance: Current guidelines for cutaneous malignant melanoma (CMM) provide general recommendations regarding surveillance while indicating that management should be tailored to patients' individual probability of recurrence. A 31-gene expression profile (31-GEP) test to predict metastatic risk has been previously validated, and classifies patients as either Class 1 (low risk) or Class 2 (high risk).

Objective: To determine the impact of the 31-GEP test's result on clinical decision-making.

Design, Setting, and Participants: Dermatology residents who attended a national educational conference were presented with clinical validity evidence for the 31-GEP. Respondents were given six CMM patient vignettes with descriptions of clinical features and answered questions about their willingness to recommend sentinel lymph node biopsy (SLNBx) or imaging based on each scenario. Additionally, respondents were asked to provide the Breslow thickness (BT), ranging from 0.7-1.5mm in 0.1mm increments, at which they would recommend SLNBx, imaging, or oncology referral.

Main Outcomes and Measures: The number of respondents who would recommend each management modality based upon three outcomes (no result, Class 1, or Class 2) was quantified. Differences between response groups were assessed using Fisher's exact test.

Results: The majority of respondents (62%, 57%, and 55%, respectively) indicated a 1.0mm BT as the guiding modality, reflecting adherence to current guidelines. After inclusion of a Class 2 result, the BT used to guide SLNBx, oncology referral, and imaging was changed in 47%, 50% and 47% of the responses, respectively, with 95%, 84% and 97% of the cases, respectively, changed in a risk-appropriate direction (decreased BT). Based on a 31-GEP Class 1 or Class 2 result, risk appropriate recommendations were more likely to be made for each management modality tested in five of the six patient vignettes (P less than 0.05).

Conclusions and Relevance: The 31-GEP test had a significant and appropriate impact on management while remaining within the context of established guidelines.

J Drugs Dermatol. 2017;16(5):428-431.


6 Article Pigmented Skin Lesion Biopsies After Computer-Aided Multispectral Digital Skin Lesion Analysis. 2015

Winkelmann, Richard R / Tucker, Natalie / White, Richard / Rigel, Darrell S. · ·J Am Osteopath Assoc · Pubmed #26501759.

ABSTRACT: BACKGROUND: The incidence of melanoma has been rising over the past century. With 37% of patients presenting to their primary care physician with at least 1 skin problem, primary care physicians and other nondermatologist practitioners have substantial opportunity to make an impact at the forefront of the disease process. New diagnostic aids have been developed to augment physician analysis of suspicious pigmented skin lesions (PSLs). OBJECTIVE: To determine the effects of computer-aided multispectral digital skin lesion analysis (MSDSLA) on dermatologists' and nondermatologist clinicians' decisions to biopsy suspicious PSLs after clinical and dermatoscopic evaluation. METHODS: Participants were shown 6 images of PSLs. For each PSL, participants were asked 3 times if they would biopsy the lesion: first after reviewing a clinical image of the PSL, again after reviewing a high-resolution dermatoscopic image, and again after reviewing MSDSLA probability findings. An answer was right if a melanoma or high-risk lesion was selected for biopsy or a low-risk lesion was not selected for biopsy. An answer was wrong if a melanoma or high-risk lesion was not selected for biopsy or a low-risk lesion was selected for biopsy. Clinicians' decisions to biopsy were evaluated using χ² analysis for proportions. RESULTS: Data were analyzed from a total of 212 participants, 177 of whom were dermatologists. Overall, sensitivity of clinical image review was 63%; dermatoscopic image review, 5%; and MSDSLA, 83%. Specificity of clinical image review was 59%; dermatoscopic image review, 40%; and MSDSLA, 76%. Biopsy decision accuracy was 61% after review of clinical images, 52% after review of dermatoscopic images, and 80% after review of MSDSLA findings. The number of lesions participants indicated that they would biopsy increased significantly, from 52% after reviewing clinical images to 63% after reviewing dermatoscopic images (P<.001). However, the overall number of specimens that participants indicated they would biopsy did not change significantly after they reviewed MSDSLA findings (53%). CONCLUSION: Sensitivity, specificity, and biopsy decision accuracy increased after clinicians reviewed MSDSLA findings. The use of objective, computer-based diagnostic aids such as MSDSLA during clinical evaluations of ambiguous PSLs could aid clinicians' decisions to biopsy such lesions.

7 Article A Quantitative System for Studying Metastasis Using Transparent Zebrafish. 2015

Heilmann, Silja / Ratnakumar, Kajan / Langdon, Erin / Kansler, Emily / Kim, Isabella / Campbell, Nathaniel R / Perry, Elizabeth / McMahon, Amy / Kaufman, Charles / van Rooijen, Ellen / Lee, William / Iacobuzio-Donahue, Christine / Hynes, Richard / Zon, Leonard / Xavier, Joao / White, Richard. ·Memorial Sloan Kettering Cancer Center, Computational Biology. · Memorial Sloan Kettering Cancer Center, Cancer Biology & Genetics. · Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program. · Massachusetts Institute of Technology, David Koch Institute for Integrated Cancer Biology. · Howard Hughes Medical Institute. · Children's Hospital Boston. · Harvard Medical School. · Dana Farber Cancer Institute. · Memorial Sloan Kettering Cancer Center, Pathology. · Weill Cornell Medical College. ·Cancer Res · Pubmed #26282170.

ABSTRACT: Metastasis is the defining feature of advanced malignancy, yet remains challenging to study in laboratory environments. Here, we describe a high-throughput zebrafish system for comprehensive, in vivo assessment of metastatic biology. First, we generated several stable cell lines from melanomas of transgenic mitfa-BRAF(V600E);p53(-/-) fish. We then transplanted the melanoma cells into the transparent casper strain to enable highly quantitative measurement of the metastatic process at single-cell resolution. Using computational image analysis of the resulting metastases, we generated a metastasis score, μ, that can be applied to quantitative comparison of metastatic capacity between experimental conditions. Furthermore, image analysis also provided estimates of the frequency of metastasis-initiating cells (∼1/120,000 cells). Finally, we determined that the degree of pigmentation is a key feature defining cells with metastatic capability. The small size and rapid generation of progeny combined with superior imaging tools make zebrafish ideal for unbiased high-throughput investigations of cell-intrinsic or microenvironmental modifiers of metastasis. The approaches described here are readily applicable to other tumor types and thus serve to complement studies also employing murine and human cell culture systems.

8 Unspecified BRAF V600E Mutation in Multiple Primary Malignancies: A Hairy Affair. 2018

White, Richard / Otaibi, Zachary / Rao, Rohit / Finley, Gene. ·Internal Medicine, Allegheny Health Network, Pittsburgh, USA. · Hematology & Oncology, Allegheny Health Network, Pittsburgh, USA. ·Cureus · Pubmed #30680261.

ABSTRACT: As the number of cancer survivors grows, so does the number of co-occurring primary malignancies and secondary malignancies. In rare cases, single driver mutations can be responsible for concomitant primary malignancies. By understanding the mechanisms that drive multiple primary malignancies (MPM), clinicians are capable of targeting molecular pathways that drive oncogenesis resulting in the successful treatment of many malignancies while also reducing the side effects of conventional chemotherapy. Herein, we report a case of co-occurring hairy cell leukemia (HCL) and malignant melanoma in a 69-year-old male. This patient tested positive for the BRAF V600E mutation and was initiated on a single agent, vemurafenib. He, unfortunately, succumbed to his illness before completion of his planned therapy course.  This case report is intended to highlight the rare co-occurrence of BRAF-positive HCL and melanoma and to encourage driver mutation evaluation when a patient presents with MPM and the possibility of a unifying driver mutation. To the best of our knowledge, this is the first case of a co-occurring BRAF positive melanoma and HCL to be reported in a chemotherapy-naïve patient.

9 Minor Impact of guidance from a computer-aided multispectral digital skin lesion analysis device on decision to biopsy lesions clinically suggestive of melanoma. 2012

Rigel, Darrell S / Roy, Mrinalini / Yoo, Jane / Cockerell, Clay J / Robinson, June K / White, Richard. · ·Arch Dermatol · Pubmed #22351788.

ABSTRACT: -- No abstract --